candesartan has been researched along with Left Ventricular Hypertrophy in 48 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension." | 9.15 | Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. ( Fujiwara, H; Matsuno, Y; Minatoguchi, S, 2011) |
| "Participants enrolled in this trial were outpatients with essential hypertension after cardiac surgery who had received candesartan for more than one year." | 9.15 | Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study. ( Hata, M; Sezai, A; Shiono, M; Soma, M; Unosawa, S; Wakui, S; Yoshitake, I, 2011) |
| "Hypertensive patients (n = 196) with echocardigraphically documented left ventricular hypertrophy were randomized to candesartan 8-16 mg/day (n = 91) or enalapril 10-20 mg/day (n = 105) with possible addition of hydrochlorothiazide (12." | 9.14 | Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co ( Ciulla, MM; Cuspidi, C; Esposito, A; Magrini, F; Muiesan, ML; Paliotti, R; Rosei, EA; Zanchetti, A, 2009) |
| "A total of 50 stable outpatients with essential hypertension who had received candesartan for more than 1 year were randomized into two groups: control group (n=25): continuous candesartan treatment at a stable dose; and olmesartan group (n=25): candesartan (8 mg day(-1)) was changed to olmesartan given at a dose of 20 mg day(-1)." | 9.14 | Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. ( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2010) |
| "Angiotensin II receptor blockers (ARB) are now commonly used to treat hypertension because of their beneficial effects on cardiovascular remodeling." | 9.12 | Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006) |
| " Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective, and well-tolerated therapy, in both the early and late phases of cardiovascular disease (prehypertension, hypertension, left ventricular hypertrophy and heart failure)." | 8.84 | Candesartan: from left ventricular hypertrophy to heart failure, a global approach. ( Barrios, V; Calderon, A; Escobar, C, 2007) |
| " Here in a double-blind, placebo-controlled, randomized study, we show that the long-term administration of the angiotensin II type 1 receptor antagonist candesartan in patients with hypertrophic cardiomyopathy was associated with the significant regression of left ventricular hypertrophy, improvement of left ventricular function, and exercise tolerance." | 6.74 | The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. ( Curila, K; Gregor, P; Kerekes, R; Krupicka, J; Marek, D; Penicka, M, 2009) |
| "Candesartan treatment resulted in a significant decrease of systolic and diastolic blood pressures, LV mass index (LVMI), homeostasis model assessment (HOMA) index, and plasma brain natriuretic peptide (BNP)." | 6.71 | Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. ( Anan, F; Hara, M; Ooie, T; Saikawa, T; Takahashi, N; Yoshimatsu, H, 2004) |
| "Candesartan cilexetil was found to be equally effective as enalapril in reducing SBP, DBP and LVMI in hypertensives with LVH, according to both ITT and PP analyses." | 6.70 | Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. ( Agabiti-Rosei, E; Cuspidi, C; Di Biagio, C; Magnani, B; Muiesan, ML; Salvetti, M; Valagussa, L; Zanchetti, A, 2002) |
| "Hypertension is the most common cause of left ventricular hypertrophy, contributing to heart failure progression." | 5.91 | Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy. ( Calleros, L; De Giusti, V; Ferrer, EG; Griera, M; Islas, MS; Jaquenod de Giusti, C; Martinez, VR; Martins Lima, A; Portiansky, EL; Rodriguez Puyol, M; Stergiopulos, N; Velez Rueda, JO; Williams, PAM, 2023) |
| "The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension." | 5.15 | Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. ( Fujiwara, H; Matsuno, Y; Minatoguchi, S, 2011) |
| "Participants enrolled in this trial were outpatients with essential hypertension after cardiac surgery who had received candesartan for more than one year." | 5.15 | Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study. ( Hata, M; Sezai, A; Shiono, M; Soma, M; Unosawa, S; Wakui, S; Yoshitake, I, 2011) |
| "Hypertensive patients (n = 196) with echocardigraphically documented left ventricular hypertrophy were randomized to candesartan 8-16 mg/day (n = 91) or enalapril 10-20 mg/day (n = 105) with possible addition of hydrochlorothiazide (12." | 5.14 | Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co ( Ciulla, MM; Cuspidi, C; Esposito, A; Magrini, F; Muiesan, ML; Paliotti, R; Rosei, EA; Zanchetti, A, 2009) |
| "To evaluate the effect of ACE inhibitor enalapril, AR blocker candesartan and their combination on left ventricular hypertrophy (LVH) and content of biochemical markers of collagen balance in patients with hypertensive LV hypertrophy." | 5.14 | [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy]. ( Ageev, FT; Ovchinnikov, AG; Serbul, VM, 2009) |
| " A total of 154 untreated hypertensive patients, aged 40 to 66 years, with World Health Organization stage I or II hypertension and left ventricular hypertrophy, were randomized to receive placebo, candesartan (32 mg), each of these plus aspirin (300 mg/d), or the same preparations in a reverse order, for 3 weeks, with a 3-week washout period between treatments." | 5.14 | Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial. ( Chiariello, M; De Rosa, ML, 2009) |
| "This study examined the influence of diabetes on left ventricular hypertrophy (LVH) detected by different electrocardiographic (ECG) criteria and its changes induced by a 12-month candesartan-based regimen." | 5.14 | Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. ( Barrios, S; Barrios, V; Calderón, A; Echarri, R; Escobar, C; Navarro-Cid, J, 2009) |
| "A total of 50 stable outpatients with essential hypertension who had received candesartan for more than 1 year were randomized into two groups: control group (n=25): continuous candesartan treatment at a stable dose; and olmesartan group (n=25): candesartan (8 mg day(-1)) was changed to olmesartan given at a dose of 20 mg day(-1)." | 5.14 | Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. ( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2010) |
| "The authors assessed the effect of an angiotensin receptor blocker (candesartan)-based regimen on electrocardiographic left ventricular hypertrophy (ECG-LVH) in 276 patients with hypertension, including 141 with the metabolic syndrome (MS)." | 5.13 | Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. ( Barrios, S; Barrios, V; Calderón, A; Echarri, R; Escobar, C; Fernandez, R; Ferrer, E; Navarro-Cid, J, 2008) |
| "Angiotensin II receptor blockers (ARB) are now commonly used to treat hypertension because of their beneficial effects on cardiovascular remodeling." | 5.12 | Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006) |
| " Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective, and well-tolerated therapy, in both the early and late phases of cardiovascular disease (prehypertension, hypertension, left ventricular hypertrophy and heart failure)." | 4.84 | Candesartan: from left ventricular hypertrophy to heart failure, a global approach. ( Barrios, V; Calderon, A; Escobar, C, 2007) |
| "The introduction of Angiotensin II receptor blockers (ARB) in 1995 was another milestone in the pharmacological management of hypertension." | 4.82 | [Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. ( Battegay, E; Zeller, A, 2005) |
| "Candesartan reduced both ventricular and atrial arrhythmias in the TAC mice, presumably by preventing the electrical remodeling by inhibiting the AT(1) receptor." | 3.73 | Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy. ( Horie, M; Kobori, A; Kuwahara, K; Makiyama, T; Yasuno, S; Zankov, DP; Zhang, C, 2006) |
| "In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which compared bedtime or awakening dosing of candesartan (+diuretics as needed) among subjects with home systolic BP (SBP) higher than 135 mm Hg, we evaluated 180 hypertensive patients who successfully underwent pulse wave analysis by HEM-9000AI and measured their urinary albumin/creatinine ratio (UACR) and left ventricular mass index (LVMI) (n = 144) at baseline and after 6 months of treatment." | 2.80 | Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Kario, K; Shimizu, M; Yano, Y, 2015) |
| " Here in a double-blind, placebo-controlled, randomized study, we show that the long-term administration of the angiotensin II type 1 receptor antagonist candesartan in patients with hypertrophic cardiomyopathy was associated with the significant regression of left ventricular hypertrophy, improvement of left ventricular function, and exercise tolerance." | 2.74 | The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. ( Curila, K; Gregor, P; Kerekes, R; Krupicka, J; Marek, D; Penicka, M, 2009) |
| "In 404 patients with left ventricular hypertrophy, a significantly larger decrease in left ventricular mass index 3 years after enrollment was observed in candesartan-based (n = 205) than amlodipine-based (n = 199) regimens (-22." | 2.73 | ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. ( Fujimoto, A; Nakao, K; Ogihara, T; Saruta, T, 2008) |
| "Electrocardiographic left ventricular hypertrophy (ECG LVH) is a powerful independent predictor of cardiovascular morbidity and mortality in hypertension." | 2.73 | Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. ( Dunn, FG; Granger, CB; Hawkins, NM; McMurray, JJ; Michelson, EL; Ostergren, J; Pfeffer, MA; Pocock, SJ; Swedberg, K; Wang, D; Yusuf, S, 2007) |
| "Candesartan treatment resulted in a significant decrease of systolic and diastolic blood pressures, LV mass index (LVMI), homeostasis model assessment (HOMA) index, and plasma brain natriuretic peptide (BNP)." | 2.71 | Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. ( Anan, F; Hara, M; Ooie, T; Saikawa, T; Takahashi, N; Yoshimatsu, H, 2004) |
| "Candesartan cilexetil was found to be equally effective as enalapril in reducing SBP, DBP and LVMI in hypertensives with LVH, according to both ITT and PP analyses." | 2.70 | Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. ( Agabiti-Rosei, E; Cuspidi, C; Di Biagio, C; Magnani, B; Muiesan, ML; Salvetti, M; Valagussa, L; Zanchetti, A, 2002) |
| "Hypertension is the most common cause of left ventricular hypertrophy, contributing to heart failure progression." | 1.91 | Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy. ( Calleros, L; De Giusti, V; Ferrer, EG; Griera, M; Islas, MS; Jaquenod de Giusti, C; Martinez, VR; Martins Lima, A; Portiansky, EL; Rodriguez Puyol, M; Stergiopulos, N; Velez Rueda, JO; Williams, PAM, 2023) |
| "Cardiac complications were defined as left ventricular hypertrophy (LVH) and ischemic heart disease (IHD)." | 1.35 | Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. ( Fujimoto, A; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2009) |
| "Candesartan (3 mg /kg/d) was given in rat chow for 4 months." | 1.33 | Effects of long-term treatment with candesartan on hemodynamics and organ damage in spontaneously hypertensive rats. ( Chen, YY; Miao, CY; Shen, FM; Su, DF; Xie, HH, 2005) |
| "Candesartan was mixed in rat chow at an estimated dose of 3 mg/kg/day." | 1.32 | Effects of long-term treatment with candesartan on organ damages in sinoaortic denervated rats. ( Liu, JG; Miao, CY; Su, DF; Xie, HH, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 34 (70.83) | 29.6817 |
| 2010's | 12 (25.00) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Martinez, VR | 1 |
| Martins Lima, A | 1 |
| Stergiopulos, N | 1 |
| Velez Rueda, JO | 1 |
| Islas, MS | 1 |
| Griera, M | 1 |
| Calleros, L | 1 |
| Rodriguez Puyol, M | 1 |
| Jaquenod de Giusti, C | 1 |
| Portiansky, EL | 1 |
| Ferrer, EG | 1 |
| De Giusti, V | 1 |
| Williams, PAM | 1 |
| Helske-Suihko, S | 1 |
| Laine, M | 1 |
| Lommi, J | 1 |
| Kaartinen, M | 1 |
| Werkkala, K | 1 |
| Kovanen, PT | 1 |
| Kupari, M | 1 |
| Shimizu, M | 2 |
| Hoshide, S | 1 |
| Ishikawa, J | 1 |
| Yano, Y | 1 |
| Eguchi, K | 1 |
| Kario, K | 1 |
| Kato, S | 1 |
| Onishi, K | 1 |
| Yamanaka, T | 1 |
| Takamura, T | 1 |
| Dohi, K | 1 |
| Yamada, N | 1 |
| Wada, H | 1 |
| Nobori, T | 1 |
| Ito, M | 1 |
| Ogihara, T | 3 |
| Fujimoto, A | 3 |
| Nakao, K | 3 |
| Saruta, T | 3 |
| Penicka, M | 1 |
| Gregor, P | 1 |
| Kerekes, R | 1 |
| Marek, D | 1 |
| Curila, K | 1 |
| Krupicka, J | 1 |
| Ciulla, MM | 1 |
| Paliotti, R | 1 |
| Esposito, A | 1 |
| Cuspidi, C | 3 |
| Muiesan, ML | 2 |
| Rosei, EA | 1 |
| Magrini, F | 1 |
| Zanchetti, A | 3 |
| Ueshima, K | 2 |
| Yasuno, S | 2 |
| Oba, K | 1 |
| Ovchinnikov, AG | 1 |
| Serbul, VM | 1 |
| Ageev, FT | 1 |
| De Rosa, ML | 1 |
| Chiariello, M | 1 |
| Barrios, V | 5 |
| Escobar, C | 5 |
| Calderón, A | 5 |
| Echarri, R | 2 |
| Barrios, S | 2 |
| Navarro-Cid, J | 2 |
| Tsutamoto, T | 1 |
| Nishiyama, K | 1 |
| Yamaji, M | 1 |
| Kawahara, C | 1 |
| Fujii, M | 1 |
| Yamamoto, T | 2 |
| Horie, M | 2 |
| Ocaranza, MP | 1 |
| Lavandero, S | 1 |
| Jalil, JE | 1 |
| Moya, J | 1 |
| Pinto, M | 1 |
| Novoa, U | 1 |
| Apablaza, F | 1 |
| Gonzalez, L | 1 |
| Hernandez, C | 1 |
| Varas, M | 1 |
| Lopez, R | 1 |
| Godoy, I | 1 |
| Verdejo, H | 1 |
| Chiong, M | 1 |
| Dahl, JS | 1 |
| Videbaek, L | 1 |
| Poulsen, MK | 1 |
| Pellikka, PA | 1 |
| Veien, K | 1 |
| Andersen, LI | 1 |
| Haghfelt, T | 1 |
| Møller, JE | 1 |
| Ishimitsu, T | 2 |
| Honda, T | 2 |
| Ohno, E | 1 |
| Furukata, S | 1 |
| Sudo, Y | 1 |
| Nakano, N | 1 |
| Takahashi, T | 1 |
| Ono, H | 2 |
| Matsuoka, H | 2 |
| Benedetto, U | 1 |
| Melina, G | 1 |
| Refice, S | 1 |
| di Bartolomeo, R | 1 |
| Roscitano, A | 1 |
| Angeloni, E | 1 |
| Sinatra, R | 1 |
| Matsuno, Y | 1 |
| Minatoguchi, S | 1 |
| Fujiwara, H | 1 |
| Oghlakian, GO | 1 |
| Sipahi, I | 1 |
| Fang, JC | 1 |
| Tomiyama, H | 1 |
| Yoshida, M | 1 |
| Yamada, J | 1 |
| Matsumoto, C | 1 |
| Odaira, M | 1 |
| Shiina, K | 1 |
| Yamashina, A | 1 |
| Sezai, A | 1 |
| Soma, M | 1 |
| Hata, M | 1 |
| Yoshitake, I | 1 |
| Unosawa, S | 1 |
| Wakui, S | 1 |
| Shiono, M | 1 |
| Valagussa, L | 1 |
| Salvetti, M | 1 |
| Di Biagio, C | 1 |
| Agabiti-Rosei, E | 1 |
| Magnani, B | 1 |
| Itoh, M | 1 |
| Takeishi, Y | 1 |
| Nakada, S | 1 |
| Miyamoto, T | 1 |
| Tsunoda, Y | 1 |
| Takahashi, H | 1 |
| Kubota, I | 1 |
| Tomoike, H | 1 |
| Piuhola, J | 1 |
| Szokodi, I | 1 |
| Kinnunen, P | 1 |
| Ilves, M | 1 |
| deChâtel, R | 1 |
| Vuolteenaho, O | 1 |
| Ruskoaho, H | 1 |
| Xie, HH | 2 |
| Miao, CY | 2 |
| Liu, JG | 1 |
| Su, DF | 2 |
| Zhou, MS | 1 |
| Adam, AG | 1 |
| Jaimes, EA | 1 |
| Raij, L | 1 |
| Tokuda, K | 1 |
| Kai, H | 1 |
| Kuwahara, F | 1 |
| Yasukawa, H | 1 |
| Tahara, N | 1 |
| Kudo, H | 1 |
| Takemiya, K | 1 |
| Koga, M | 1 |
| Imaizumi, T | 1 |
| Leonetti, G | 1 |
| Mizukami, M | 1 |
| Hasegawa, H | 1 |
| Kohro, T | 1 |
| Toko, H | 1 |
| Kudoh, S | 1 |
| Zou, Y | 1 |
| Aburatani, H | 1 |
| Komuro, I | 1 |
| Anan, F | 1 |
| Takahashi, N | 1 |
| Ooie, T | 1 |
| Hara, M | 1 |
| Yoshimatsu, H | 1 |
| Saikawa, T | 2 |
| de Boer, RA | 1 |
| Pokharel, S | 1 |
| Flesch, M | 1 |
| van Kampen, DA | 1 |
| Suurmeijer, AJ | 1 |
| Boomsma, F | 1 |
| van Gilst, WH | 1 |
| van Veldhuisen, DJ | 1 |
| Pinto, YM | 1 |
| Nakagawa, M | 1 |
| Sano, N | 1 |
| Nobe, S | 1 |
| Ichinose, M | 1 |
| Yonemochi, H | 1 |
| Higashikuni, Y | 1 |
| Sata, M | 1 |
| Nagai, R | 1 |
| Zeller, A | 1 |
| Battegay, E | 1 |
| Kobayashi, T | 1 |
| Takahashi, M | 1 |
| Minami, J | 1 |
| Ohta, S | 1 |
| Inada, H | 1 |
| Yoshii, M | 1 |
| Chen, YY | 1 |
| Shen, FM | 1 |
| Zhang, C | 1 |
| Kuwahara, K | 1 |
| Zankov, DP | 1 |
| Kobori, A | 1 |
| Makiyama, T | 1 |
| Taniguchi, I | 1 |
| Kawai, M | 1 |
| Date, T | 1 |
| Yoshida, S | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Mochizuki, S | 2 |
| Hawkins, NM | 1 |
| Wang, D | 1 |
| McMurray, JJ | 1 |
| Pfeffer, MA | 1 |
| Swedberg, K | 1 |
| Granger, CB | 1 |
| Yusuf, S | 1 |
| Pocock, SJ | 1 |
| Ostergren, J | 1 |
| Michelson, EL | 1 |
| Dunn, FG | 1 |
| Vegazo, O | 2 |
| Fernandez, R | 3 |
| Asín, E | 1 |
| Tomás, JP | 1 |
| Ruiz, S | 1 |
| Moya, JL | 1 |
| Megías, A | 1 |
| Grandi, AM | 1 |
| Solbiati, F | 1 |
| Laurita, E | 1 |
| Maresca, AM | 1 |
| Nicolini, E | 1 |
| Marchesi, C | 1 |
| Gianni, M | 1 |
| Guasti, L | 1 |
| Venco, A | 1 |
| Ferrer, E | 1 |
| Nakamoto, M | 1 |
| Ohya, Y | 1 |
| Shinzato, T | 1 |
| Mano, R | 1 |
| Yamazato, M | 1 |
| Sakima, A | 1 |
| Takishita, S | 1 |
| Sugimoto, K | 1 |
| Fujimura, A | 1 |
| Takasaki, I | 1 |
| Tokita, Y | 1 |
| Iwamoto, T | 1 |
| Takizawa, T | 1 |
| Gotoh, E | 1 |
| Shionoiri, H | 1 |
| Ishii, M | 1 |
| Ikeda, Y | 1 |
| Nakamura, T | 1 |
| Takano, H | 1 |
| Kimura, H | 1 |
| Obata, JE | 1 |
| Takeda, S | 1 |
| Hata, A | 1 |
| Shido, K | 1 |
| Yoshida, Y | 1 |
| Yamakawa, H | 1 |
| Imamura, T | 1 |
| Matsuo, T | 1 |
| Onitsuka, H | 1 |
| Tsumori, Y | 1 |
| Kato, J | 1 |
| Kitamura, K | 1 |
| Koiwaya, Y | 1 |
| Eto, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves[NCT00699452] | Phase 3 | 120 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study[NCT00430833] | Phase 2 | 0 participants | Interventional | Active, not recruiting | |||
| Beneficio Del Bloqueo Del Sistema Renina-angiotensina Sobre la evolución clínica y el Remodelado Ventricular Tras la colocación de Una prótesis percutánea aórtica (RASTAVI)[NCT03201185] | Phase 4 | 194 participants (Actual) | Interventional | 2018-02-10 | Active, not recruiting | ||
| Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction[NCT03837470] | Early Phase 1 | 14 participants (Actual) | Interventional | 2019-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for candesartan and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2011 |
Left ventricular hypertrophy regression with antihypertensive treatment: focus on Candesartan.
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Electrocardiography; Hu | 2003 |
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Ty | 2005 |
Candesartan: from left ventricular hypertrophy to heart failure, a global approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2007 |
23 trials available for candesartan and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Is blockade of the Renin-Angiotensin system able to reverse the structural and functional remodeling of the left ventricle in severe aortic stenosis?
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazo | 2015 |
Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
Exaggerated hypertensive response to exercise in patients with diastolic heart failure.
Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; B | 2008 |
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2008 |
The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 2009 |
Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2009 |
[Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aspirin; Benzimidazol | 2009 |
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Complications; | 2009 |
Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2010 |
Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazo | 2010 |
Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-C | 2010 |
Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 2011 |
Arterial-cardiac destiffening following long-term antihypertensive treatment.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Ankle Brachial Index; Antihypertensive Agents; B | 2011 |
Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
Topics: Aged; Aldosterone; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; An | 2011 |
Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Echocardiography | 2002 |
Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Mas | 2004 |
Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphe | 2005 |
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl | 2006 |
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2007 |
Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Echoca | 2006 |
Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2008 |
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Pre | 2008 |
21 other studies available for candesartan and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Hypertension; Hypertrophy, Lef | 2023 |
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial.
Topics: Adrenergic Antagonists; Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calciu | 2009 |
Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2010 |
Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular organ injuries in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; D | 2010 |
Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Com | 2011 |
Long-term treatment with angiotensin II type 1 receptor antagonist, CV-11974, restores beta-catenin mRNA expression in volume-overloaded rabbit hearts.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; beta Catenin; Bi | 2002 |
Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Animals, Genetically Mod | 2003 |
Effects of long-term treatment with candesartan on organ damages in sinoaortic denervated rats.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Denervation; Hypertrophy, Left Ventricular; Kidney; Mal | 2003 |
In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Co | 2003 |
Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Co | 2004 |
Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; B | 2003 |
Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atr | 2004 |
Patients with mild hypertensive heart disease and left ventricular outflow tract obstruction: treatment with angiotensin II antagonists.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2004 |
Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.
Topics: Aged; Aspirin; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Chest Pain; Drug Therapy | 2005 |
Effects of long-term treatment with candesartan on hemodynamics and organ damage in spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Aorta; Baroreflex; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2005 |
Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Com | 2006 |
Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug E | 2007 |
Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Fibrosis; Hypertension; Hypertrophy, Lef | 2008 |
Effects of renin-angiotensin system blockade and dietary salt intake on left ventricular hypertrophy in Dahl salt-sensitive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1998 |
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Diastolic wall stress and ANG II in cardiac hypertrophy and gene expression induced by volume overload.
Topics: Adrenomedullin; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; | 2000 |